Ascletis Pharma Inc.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2022🗂️ Report periods on file: 2022, 2021, 2018

In its 2022 reporting, Ascletis Pharma Inc. disclosed greenhouse gas emissions of 2.3K tCO2e/year (Scope 1 & 2). By scope: Scope 1: 22.28 tCO2e/year; Scope 2: 2.2K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
2.3K tCO2e/year (Scope 1 & 2)
2022
💧
Water Usage
24.4K m3/year
2022
♻️
Waste
160.64 tons/year (hazardous and non-hazardous)
2022
⚙️
Energy Use
3.8M kWh/year
2022

📊 Emissions by Scope (2022)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).22.28 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.2.2K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
20222.3K tCO2e/year (Scope 1 & 2)
20212.2K tonnes carbon dioxide equivalent
20182.1K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Maintain or decrease GHG emission intensity in 2025 (using 2021 as the base year)
  • Maintain or decrease waste generation intensity in 2025 (using 2021 as the base year)
  • Maintain or decrease electricity consumption intensity in 2025 (using 2021 as the base year)
  • Maintain or decrease water consumption intensity in 2025 (using 2021 as the base year)

🌱 ESG Focus Areas

Innovation-Driven and Collaborative CooperationCommitment to Quality and IntegrityTalent ManagementEnvironmental Protection for a Green World

⚠️ Challenges & Risks +

  • Intense competition in the market for antiviral drugs
  • Uncertainty in obtaining regulatory approval for drug candidates
  • Dependence on successful development and approval of drug pipeline for financial prospects
  • Potential for drug candidates to fail to achieve market acceptance
  • Risks associated with in-licensed drug candidates and strategic alliances
  • Potential for unsuccessful patent protection
  • Difficulty in attracting and retaining senior management and key scientific employees
  • Physical risks from extreme high temperature and water scarcity
  • Transition risks from international climate change policy and regulatory requirements
  • Stakeholder focus on climate-related issues

📋 Report Information

Reporting Period: 2022
Frameworks: Appendix 27 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited